Goldshield
Critical Care Europe has a vision to create truly significant
hospital business in Europe that expands our product, services
and markets providing added value solutions to all our customers,
reaching them either directly or by establishing marketing
partners wherever appropriate and through the most appropriate
distribution channels.
Expanding
Product Portfolio
In line with the company vision, Goldshield Critical Care
Europe has entered into an exclusive agreement with a number
of innovative companies to bring their products to a wider
EU market. These include medical devices such as AutoDetect™
and Noseeze™
and our collaboration with United Therapeutics..
The
company has recently developed a new therapy area of Oncology
both through acquisition and in-house development launching
products such as Methotrexate,
Thiotepa, Amsidine™(amsacrine),
Cisplatin and Fluorouracil
and has launched a range of innovative medical devices throughout
Europe. We are fully committed to further expand our oncology
product portfolio to provide wider product basket in this
therapy area with a number of new cytotoxic drugs in the pipeline
for the year 2006-2007.
Goldshield
Critical Care Europe will maintain a product pipeline which
offers an increasing portfolio of niche products for hospitals
throughout the U.K., Ireland and Europe which will increase
our product offering and value to our customers.
